Chris Katje
Research analyst, growth, value, IPOs

Ligand Pharmaceuticals: 2014 Run Not Done With Short And Long-Term Catalysts Coming

Executive summary:

· Ligand Pharmaceuticals has 85 fully funded programs in trials

· Recently approved Duavive could provide upside to 2014 guidance

· Strong gross margins and low share count provides huge profits for shareholders

· Unpartnered drug provides catalyst for short term

· Alzheimer's drug with Merck could be a huge blockbuster if approved

Back in October, I highlighted a drug company that I believed could provide huge returns for shareholders going forward. Since that time, shares of Ligand Pharmaceuticals (NASDAQ:LGND) have shot up over 60%. It was that same bullishness and new catalysts that gave Ligand a spot on my annual top ten stock picks list. Since the beginning of the year, shares of Ligand...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details